Your browser doesn't support javascript.
loading
Deep vein thrombosis and pulmonary embolism: a prospective, observational study to evaluate diagnostic performance of the Tina-quant D-Dimer Gen.2 assay.
Bertsch, Thomas; Behringer, Wilhelm; Blaschke, Sabine; Body, Richard; Davidson, Simon; Müller-Olling, Mirco; Guo, Ge; Rieger, Anna; Wahl, Annika; Horner, Daniel; Sun, Yuli; Turnes, Lucia; Sonner, Ulrich; Hoffmann, Michael.
Affiliation
  • Bertsch T; Institute of Clinical Chemistry, Laboratory Medicine and Transfusion Medicine, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany.
  • Behringer W; Department of Emergency Medicine, Faculty of Medicine, University of Jena, Jena, Germany.
  • Blaschke S; Emergency Department, University Medical Center Göttingen, Göttingen, Germany.
  • Body R; Division of Cardiovascular Sciences, Core Technology Facility, University of Manchester, Manchester, United Kingdom.
  • Davidson S; Emergency Department, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
  • Müller-Olling M; Roche Diagnostics International Ltd, Rotkreuz, Switzerland.
  • Guo G; Roche Diagnostics GmbH, Mannheim, Germany.
  • Rieger A; Roche Diagnostics, Indianapolis, IN, United States.
  • Wahl A; Roche Diagnostics GmbH, Penzberg, Germany.
  • Horner D; Roche Diagnostics GmbH, Penzberg, Germany.
  • Sun Y; Emergency Department, Salford Royal NHS Foundation Trust, Salford, United Kingdom.
  • Turnes L; Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, United Kingdom.
  • Sonner U; Roche Diagnostics GmbH, Penzberg, Germany.
  • Hoffmann M; Agent Representing Roche Diagnostics GmbH, Penzberg, Germany.
Front Cardiovasc Med ; 10: 1142465, 2023.
Article in En | MEDLINE | ID: mdl-38169956
ABSTRACT

Background:

D-Dimer testing is a diagnostic tool for exclusion of deep vein thrombosis (DVT) and pulmonary embolism (PE). This study evaluated the diagnostic performance of the Tina-quant® D-Dimer Gen.2 assay (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) in patients with low/intermediate pre-test probability of DVT/PE using standard, age-, and clinical probability-adjusted cut-offs.

Methods:

In this prospective, observational, multicenter study (July 2017-August 2019), plasma samples were collected from hospital emergency departments and specialist referral centers. DVT/PE was diagnosed under hospital standard procedures and imaging protocols. A standard D-dimer cut-off of 0.5 µg fibrinogen equivalent units (FEU)/ml was combined with the three-level Wells score; cut-offs adjusted for age (age × 0.01 µg FEU/ml for patients >50 years) and clinical probability (1 µg FEU/ml for low probability) were also evaluated. An assay comparison was conducted in a subset of samples using the Tina-quant D-Dimer Gen.2 assay and the previously established routine laboratory assay, STA-Liatest D-Di Plus assay (Stago Deutschland GmbH, Düsseldorf, Germany).

Results:

2,897 patients were enrolled; 2,516 completed the study (DVT cohort 1,741 PE cohort 775). Clinical assessment plus D-dimer testing using the standard cut-off resulted in 317 (DVT) and 230 (PE) false positives, and zero (DVT) and one (PE) false negatives. Negative predictive value (NPV) was 100.0% (95% confidence interval [CI] 99.7%-100.0%) and 99.8% (95% CI 98.8%-100.0%) for DVT and PE, respectively. After age-adjustment, NPV was 99.9% (95% CI 99.6%-100.0%) and 99.1% (95% CI 97.8-99.7) for DVT and PE, respectively. False positive rates decreased (>50%) in clinical probability-adjusted analyses vs. primary analysis. In the assay comparison, the performances of the two assays were comparable.

Conclusion:

The Tina-quant D-Dimer Gen.2 assay and standard D-dimer cut-off level combined with the three-level Wells score accurately identified patients with a very low probability of DVT/PE.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Front Cardiovasc Med Year: 2023 Document type: Article Affiliation country: Germany Country of publication: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Front Cardiovasc Med Year: 2023 Document type: Article Affiliation country: Germany Country of publication: Switzerland